What is Ra Pharmaceuticals Earnings Power Value (EPV)?
As of Dec19, Ra Pharmaceuticals's earnings power value is $5.51. *
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.
Margin of Safety is
N/A.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.
Ra Pharmaceuticals Earnings Power Value (EPV) Historical Data
The historical data trend for Ra Pharmaceuticals's Earnings Power Value (EPV) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ra Pharmaceuticals Earnings Power Value (EPV) Chart
|
Ra Pharmaceuticals Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
| Earnings Power Value (EPV) |
|
Get a 7-Day Free Trial
|
- |
- |
- |
- |
- |
|
Ra Pharmaceuticals Quarterly Data
|
|
Dec14 |
Sep15 |
Dec15 |
Mar16 |
Jun16 |
Sep16 |
Dec16 |
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
| Earnings Power Value (EPV) |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Ra Pharmaceuticals's Earnings Power Value (EPV)
For the Biotechnology subindustry, Ra Pharmaceuticals's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ra Pharmaceuticals's Earnings Power Value (EPV) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ra Pharmaceuticals's Earnings Power Value (EPV) distribution charts can be found below:
* The bar in red indicates where Ra Pharmaceuticals's Earnings Power Value (EPV) falls into.
Ra Pharmaceuticals Earnings Power Value (EPV) Calculation
Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.
The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.
Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
87 Cambridge Park Drive, Cambridge, MA, USA, 02140
Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.
Executives
| Peter Kolchinsky |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Edward T Mathers |
director |
C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
| Timothy R Pearson |
director |
C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
| Aoife Brennan |
director |
200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139 |
| Douglas A Treco |
director, officer: President and CEO |
87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
| Nea Partners 13, Limited Partnership |
10 percent owner |
1119 ST. PAUL STREET, BALTIMORE MD 21202 |
| Nea 13 Gp, Ltd |
10 percent owner |
1119 ST. PAUL STREET, BALTIMORE MD 21202 |
| New Enterprise Associates 13 Lp |
10 percent owner |
1119 ST PAUL STREET, BALTIMORE MD 21202 |
| Rajeev M. Shah |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Alexander Cumbo |
director |
215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
| Robert Heft |
director |
87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
| Patrick J Kerins |
10 percent owner |
|
| Ra Capital Management, L.p. |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Ra Capital Healthcare Fund Lp |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| David Charles Lubner |
officer: Executive VP and CFO |
C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Ra Pharmaceuticals (Ra Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RARX has been successfully added to your